No acceleration in healing to the best of my knowledge
Clinical practice guidelines[20, 21] have recommended the use of SGLT2i in individuals at higher risk of HF, while GLP-1RA may be prioritized in those with T2DM at higher ASCVD risk (calculated 10-year ASCVD risk 10%, Class IIa, level of evidence: B) given their neutral effect on HF hospitalization [22]
May 2024 The MDL remained open and had not been officially closed
Biological characteristics of GLP-1RAs Molecular structure and pharmacological properties Due to the suboptimal in vivo stability of the native GLP-1 peptide, GLP-1RAs were engineered with structural modifications that mimic endogenous GLP-1 while achieving a prolonged duration of action [15]
rs6276, rs6277, and rs1800497) in the DRD2 gene are associated with decreased D 2 R expression and function attributable to decreased D 2 R messenger RNA stability and synthesis of the receptor and are associated with elevated blood pressure and hypertension [10, 39]